We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Presents Cutting-Edge Point-Of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 12 Nov 2024

EKF Diagnostics (Cardiff, Wales, UK) is attending MEDICA 2004 where the company is showcasing its diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care (POC) testing and life sciences applications. More...

EKF leads the way with cutting-edge POC diagnostic solutions that empower healthcare professionals and patients with rapid, accurate, and accessible testing capabilities and results. The company’s technologies enable informed decision-making, timely interventions, and improved patient outcomes at the POC. At this year’s MEDICA, EKF is demonstrating its POC medical devices and in-vitro diagnostic (IVD) tests for use at or near the patient’s location, engineered for fast and precise results, allowing healthcare professionals to make swift decisions. This includes EKF’s diabetes POC analyzers that measure glucose, lactate, glycated hemoglobin (HbA1C), and whole blood beta-hydroxybutyrate (BHB). These analyzers offer rapid and reliable results, giving practitioners and patients the critical information needed for clinical or lifestyle decisions within minutes. Among EKF’s diabetes point-of-care analyzers exhibited at MEDICA 2024 are Biosen C-Line, Quo-Test, STAT-Site WB, and Quo-Lab. The new Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer, has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the device to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians.

EKF’s hemoglobin POC analyzers exhibited at MEDICA 2024 offer quick and convenient on-site blood testing, minimizing result turnaround times and enhancing patient diagnosis and outcomes. These include the DiaSpect Tm hand-held hemoglobin analyzer and Hemo Control POC hemoglobin analyzer that provides quantitative, lab-quality hemoglobin results after 25 seconds. Both devices are powered by EKF Link, which is an optional software platform that provides a flexible and secure method for connecting POC devices to hospital and laboratory IT systems. EKF Link is a middleware solution that helps healthcare providers manage their POC analyzers and associated data on one platform. A flexible and open solution that can be interfaced with most POC analyzers, allowing real-time data management, including patient test results, QC results, operator management, and analyzer configuration.

Related Links:
EKF Diagnostics


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Clostridium Difficile Test
Immunocard Toxins A&B
New
Respiratory Infections Test
STANDARD Q Adeno Respi Ag Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.